NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
Clinical Trials
43 trialsNCT07071961 2026-02-17
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
NCT07213570 2025-12-17
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT02368886 2025-06-18
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT06949982 2025-05-04
x-МАР
Pavlov First Saint Petersburg State Medical University
Phase 2 Recruiting
NCT04450836 2025-03-30
SOREGATT
UNICANCER
Phase 2 Terminated
NCT06425133 2024-12-24
CARE
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT06575725 2024-11-21
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT02096354 2024-10-15
ROCKET
EpicentRx, Inc.
Phase 2 Completed
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT02466009 2024-09-04
Regorafenib in Metastatic Colorectal Cancer
University of Rochester
Phase 2 Completed
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT02581059 2024-06-26
Efficacy of Ginseng for Patients on Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT05900648 2024-04-29
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT02316340 2024-01-05
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02195011 2023-12-05
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
Phase 2 Completed
NCT05985109 2023-10-26
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT05970705 2023-08-01
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Fudan University
Phase 2 Recruiting
NCT04126733 2023-07-18
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
Phase 2 Completed
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT05382741 2023-05-17
VIVA
Ospedale Policlinico San Martino
Phase 2 Unknown
NCT05524155 2022-09-01
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03099486 2022-02-07
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Fox Chase Cancer Center
Phase 2 Terminated
NCT05130021 2021-12-06
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Maxinovel Pty., Ltd.
Phase 2 Unknown
NCT01298570 2021-01-06
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02835924 2020-03-10
RE-ARRANGE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT02425683 2020-02-10
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
Phase 2 Terminated
NCT02651415 2019-09-12
PARICCA
British Columbia Cancer Agency
Phase 2 Completed
NCT03880877 2019-03-21
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 2 Unknown
NCT02699073 2019-02-28
TEXCAN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT02465502 2018-11-07
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Bayer
Phase 2 Completed
NCT01949194 2018-08-10
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Jewish General Hospital
Phase 2 Unknown
NCT02119676 2018-02-13
Study of Ruxolitinib in Colorectal Cancer Patients
Incyte Corporation
Phase 2 Terminated
NCT01875380 2017-08-01
REFRAME
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT02175654 2017-08-01
PREVIUM
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Terminated
NCT01289821 2017-03-15
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Bayer
Phase 2 Completed